1. Home
  2. SEED vs BCDA Comparison

SEED vs BCDA Comparison

Compare SEED & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

N/A

Current Price

$1.02

Market Cap

12.3M

ML Signal

N/A

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.91

Market Cap

13.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
BCDA
Founded
1997
N/A
Country
China
United States
Employees
N/A
21
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
13.6M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
SEED
BCDA
Price
$1.02
$0.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
13.5K
717.1K
Earning Date
01-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$0.78
52 Week High
$2.49
$2.42

Technical Indicators

Market Signals
Indicator
SEED
BCDA
Relative Strength Index (RSI) 43.65 42.24
Support Level $0.96 $0.81
Resistance Level $1.09 $1.31
Average True Range (ATR) 0.04 0.10
MACD 0.00 -0.03
Stochastic Oscillator 25.08 18.18

Price Performance

Historical Comparison
SEED
BCDA

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: